FindTrial
Sign In

Efficacy of Short-Term Intravenous Hydrocortisone Vesus Intravenous Metylprednisolone in Acute Exacerbation of COPD

Efficacy of Short-Term Intravenous Hydrocortisone Versus Intravenous Methylprednisolone Regimens in Acute Exacerbation of COPD:An Open Label,Parallel Group,Randomized Controlled Equivalence Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/053207
Enrollment
160
Registered
2023-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J209- Acute bronchitis, unspecified

Interventions

Intervention1: INTRAVENOUS HYDROCORTISONE: INTRAVENOUS HYDROCORTISONE 100 MG 8 TDS FOR 5 DAYS Control Intervention1: INTRAVENOUS METHYLPREDNISOLONE: INTRAVENOUS METHYLPREDNISOLONE 125 MG TDS FOR 5 DAY

Sponsors

UCMS AND GTB HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All AECOPD requiring hospitalization Age >40 years Written informed consent

Exclusion criteria

Exclusion criteria: Personal or family history of asthma,atopy,or allergic disease use of systemic steroids within past 30 days Decompensated CHF Known malignancy Immunosuppressed state Respiratory failure requiring mechanical ventilation Hemodynamically unstable patients Pregnancy or lactation Previous enrolment in this study or any other study

Design outcomes

Primary

MeasureTime frame
Comparison of improvement in CAT Score between both groupsTimepoint: Improvement of CAT score ON DAY 5—

Secondary

MeasureTime frame
Length of hospital stay Morbidity MortalityTimepoint: DURING INDEX ADMISSION—

Countries

India

Contacts

Public ContactINDU LOCHAB

UCMS and GTB Hospital

shivanarang@gmail.com9899838807

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026